FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
22. Oktober 2024 07:00 ET
|
CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
27. August 2024 07:00 ET
|
CytoSorbents
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
13. August 2024 16:19 ET
|
CytoSorbents
New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarterIn Q2 2024, increased product sales by...
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
13. August 2024 16:18 ET
|
CytoSorbents
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
07. August 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Report Q2 2024 Financial and Operating Results
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
05. Juni 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
04. Juni 2024 07:00 ET
|
CytoSorbents
CTSO STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024
CytoSorbents Reports First Quarter 2024 Results
09. Mai 2024 16:17 ET
|
CytoSorbents
CytoSorbents Reports First Quarter 2024 Results
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
02. Mai 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
26. April 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Report First Quarter 2024 Operating and Financial Results